FOLH1 and urinary system neoplasm: Tumor-related antigens commonly expressed in urinary system tumors and other solid tumors have shown good anti-tumor activity in preclinical or clinical studies, such as CAR T cells targeting PSMA, EGFR, MUC1, etc. Therefore, the use of CAR T cell therapy in urologic tumors may be more favorable, given the availability of target antigens expressed more frequently than is observed in other solid tumors.